![](/__local/2/55/17/D68A61DD08ACCEE898E3649BF1C_B2F31256_1586A.png)
王博
讲师,硕士生导师
电子信箱:wangbo0601@zzu.edu.cn wangbo6329@163.com
联系方式:18768872680
详细个人简介及成果发表:https://www.researchgate.net/profile/Bo-Wang-461
主要研究方向包括:(1)表观遗传关键蛋白在消化道肿瘤发生发展过程中的机制研究;(2)消化道肿瘤耐药机制及小分子干预研究;(3)痕量肿瘤标志物检测方法的开发。
个人简介
王博,女,河南南阳人,1990年生,医学博士,硕士生导师。本硕博均就读于郑州大学药学院,2019年获医学博士学位。博士就读期间赴哈佛医学院附属麻省总医院进行短期学习交流。2019年7月受聘为郑州大学药学院讲师,获“郑州大学2020年度拔尖博士”。主持国家自然科学基金青年项目、国家博士后面上基金、河南省科技攻关项目等;在《Pharmacology & Therapeutics》,《Journal of Medicinal Chemistry》,《Acta Pharmaceutica Sinica B》,《European Journal of Medicinal Chemistry》等国际知名期刊发表多篇SCI科研论文20余篇,获授权国家发明专利5项;同时任国际知名期刊Frontiers in pharmacology客座编辑,主持专刊1项。
教学与教研
承担本科及研究生课程(包括《药物化学》、《新药筛选》、《药物化学实验》、《医药数理统计》等);指导大学生创新创业训练计划3项;参与郑州大学教育教学改革研究与实践项目2项,其中1项级别为“重大项目”。
科研项目
(1) 国家自然科学基金委员会,青年项目,82103997,新型4-吲哚喹唑啉类肿瘤耐药逆转剂的设计、合成及活性机制研究,2022年1月至2024年12月,30万元,在研,主持
(2) 中国博士后科学基金面上项目,2021M692950,具有联芳基骨架的新型MDR逆转剂的设计、合成及生物学评价,2021年4月至2023年4月,8万元,结题,主持
(3) 河南省科技厅,重点研发与推广专项科技攻关,202102310145,新型表观遗传关键蛋白KDM5B抑制剂调控ABCB1介导的多药耐药的活性评价及其机制研究,2019年12月至2021年12月,10万元,结题,主持
(4) 国家自然科学基金委员会,国际(地区)合作与交流项目,82020108030,USP7对胃癌细胞转移、增殖和免疫逃逸的调节机制及小分子化合物干预研究,2021年1月至2025年12月,248万元,在研,参与
研究与成果
(1)Liang Shen#, Bo Wang#, Shao-Peng Wang, Shi-Kun Ji, Meng-Jie Fu, Shu-Wu Wang, Wen-Qing Hou, Xing-Jie Dai*, Hong-Min Liu*. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy. Journal of Medicinal Chemistry, 2024, 67, 922-951.
(2)Ning-Jie Guo#, Bo Wang#, Yu Zhang, Hui-Qin Kang, Hai-Qian Nie, Meng-Kai Feng, Xi-Ya Zhang, Li-Juan Zhao, Ning Wang, Hong-Min Liu, Yi-Chao Zheng*, Wen Li*, Ya Gao*. USP7 as an emerging therapeutic target: A key regulator of protein homeostasis. International Journal of Biological Macromolecules, 2024, 263, 130309.
(3)Yin-Rui Li#, Bo Wang#, Yi-Chao Zheng, Hui-Qin Kang, Ang He, Li-Juan Zhao, Ning-Jie Guo, Hong-Min Liu, Adil Mardinoglu, MAA Mamun, Ya Gao*, Xiao-Bing Chen*. The multifaceted r 1 ole of post-translational modifications of LSD1 in cellular processes and disease pathogenesis. Gene & Diseases, 2024, 101307.
(4)Xiao-Nan Zhang#, Ya Gao#, Xi-Ya Zhang, Ning-Jie Guo, Wen-Qing Hou, Shu-Wu Wang, Yi-Chao Zheng, Ning Wang, Hong-Min Liu*, Bo Wang*. A Systematic Review of HER2-Targeted Therapy. Pharmacology & Therapeutics, 2023. Accepted.
(5)Yuan-Zai Zhu#, Meng-Kai Feng#, Bo Wang#, Yi-Chao Zheng, Dan-Dan Jiang, Li-Juan Zhao, M.A.A. Mamun, Hui-Qin Kang, Hai-Qian Nie, Xi-Ya Zhang, Ning-Jie Guo, Shang-Shang Qin, Ning Wang, Hong-Min Liu*, Ya Gao*. New insights into the non-enzymatic function of HDAC6. Biomedicine & Pharmacotherapy, 2023, 161, 114438.
(6)Yi-Chao Zheng, Yue-Jiao Liu, Ya Gao, Bo Wang*, Hong-Min Liu*. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Recent Patents on Anti-Cancer Drug Discovery, 2022, 17,9-25.
(7)Kai Tang#, Bo Wang#, Bin Yu*, Hong-Min Liu*. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy. European Journal of Medicinal Chemistry, 2022, 227, 113967.
(8)Dan-Dan Shen#, Bo Wang#, Ya Gao, Li-Juan Zhao, Ya-Ping Bi, Jin-Ge Zhang, Ning Wang, Hui-Qin Kang, Jing-Ru Pang, Ying Liu, Lu-Ping Pang, Zhe-Sheng Chen, Yi-Chao Zheng*, Hong-Min Liu*. Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 2022, 12(5), 2193-2205.
(9)Bo Wang#, Qiu-Hua Zhang#, Xiao-Jing Li#, Sai-Qi Wang, Xiao-Bing Chen*, Bin Yu*, Hong-Min Liu*. Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment. European Journal of Medicinal Chemistry, 2021, 226, 113896.
(10)Shuo Yuan#, Bo Wang#, Qing-Qing Dai, Xiao-Nan Zhang, Jing-Ya Zhang, Jia-Hui Zuo, Hui Liu, Zhe-Sheng Chen, Guo-Bo Li, Shaomeng Wang, Hong-Min Liu,* and Bin Yu*. Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 14895-14911.
(11)Xin-Hui Zhang#, Qian Guo#, Heng-Ying Wang, Yi-Han Li, Mussa Yussuf Khamis, Li-Ying Ma, Bo Wang*, Hong-Min Liu*. Gramine-based structure optimization to enhance anti-gastric cancer activity. Bioorganic Chemistry, 2021, 107, 104549.
(12)Xin-Hui Zhang#, Bo Wang#, Yuan-Yuan Tao, Qin Ma, Hao-Jie Wang, Zhang-Xu He, Hui-Pan Wu, Yi-Han Li, Bing Zhao*, Li-Ying Ma*, Hong-Min Liu*. Thiosemicarbazone-based lead optimization to discover high efficiency and low-toxicity anti-gastric cancer agents. European Journal of Medicinal Chemistry, 2020, 199, 112349.
(13)Jing-Quan Wang#, Wang Bo#, Zi-Ning Lei, Qiu-Xu Teng, Jonathan Y. Li, Wei Zhang, Ning Jia, Chao-Yun Cai, Ma Li-Ying, Hong-Min Liu*, Zhe-Sheng Chen*. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. European Journal of Pharmacology, 2019, 863, 172611.
(14)王博,马立英,雷紫凝,李中华,赵兵,Zhe-Sheng Chen(1/6),科技成果奖(优秀科技论文奖),河南省教育厅,一等奖,证书编号:豫教[2022]22167,2022年。
(15)袁硕,王博(2/2),科技成果奖(优秀科技论文奖),河南省教育厅,一等奖,证书编号:豫教[2023]36593,2023年。